Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | MMP8 | P22894 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15600846 | 0.73 | — | — | |
| SCHEMBL22168394 | 0.71 | ALDH1A1 (0.38) | CA12CA1CA2MMP1MMP2 | |
| SCHEMBL16000785 | 0.71 | CA12 (0.36) | CA12CA1CA2MMP1MMP2 | |
| SCHEMBL22781615 | 0.68 | EPHX1 (0.38) | CA12CA1CA2MMP1MMP2 | |
| SCHEMBL14337325 | 0.68 | CA12 (0.38) | CA12CA1CA2MMP1MMP2 | |
| SCHEMBL5526191 | 0.67 | — | — | |
| SCHEMBL16232685 | 0.67 | EPHX1 (0.33) | CA12CA1CA2MMP1MMP2 | |
| SCHEMBL10127347 | 0.65 | — | — | |
| SCHEMBL19668989 | 0.65 | EPHX1 (0.40) | CA12CA1CA2MMP1MMP2 | |
| SCHEMBL19668996 | 0.64 | MMP1 (0.34) | CA12CA1CA2MMP1MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210315894-A9 | 4,6-PYRIMIDINYLENE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-10-14 | — | — | US | disclosed |
| US-10906889-B2 | Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| US-20200338075-A1 | 4,6-PYRIMIDINYLENE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-10-29 | — | — | US | disclosed |
| US-10695346-B2 | 4,6-pyrimidinylene derivatives and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-20190031642-A1 | POLYCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | PARAZA PHARMA, INC. (CA) | 2019-01-31 | — | — | US | disclosed |
| US-20180110778-A1 | 4,6-PYRIMIDINYLENE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200338075-A1 | 4,6-PYRIMIDINYLENE DERIVATIVES AND USES THEREOF | CDK3, CDK1, CDK14 | CA12 3991/4885CA1 3255/4885CA2 2114/4885 |
| US-10906889-B2 | Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7) | CDK13, CDK3, CDK12 | CA12 1396/4885CA1 1665/4885CA2 1520/4885 |
| US-10695346-B2 | 4,6-pyrimidinylene derivatives and uses thereof | CDK3, CDK1, CDK14 | CA12 3991/4885CA1 3255/4885CA2 2114/4885 |
| US-20190031642-A1 | POLYCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK13, CDK3, CDK12 | CA12 1396/4885CA1 1665/4885CA2 1520/4885 |
| US-20210315894-A9 | 4,6-PYRIMIDINYLENE DERIVATIVES AND USES THEREOF | CDK3, CDK1, CDK14 | CA12 3991/4885CA1 3255/4885CA2 2114/4885 |
| US-20180110778-A1 | 4,6-PYRIMIDINYLENE DERIVATIVES AND USES THEREOF | CDKL4, CDKL5, PIP5K1A | CA12 4677/4885CA1 3514/4885CA2 2339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.